Startseite>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Tunicamycin Mixture

Tunicamycin Mixture

Katalog-Nr.GC16738

Antibiotikum, hemmt GlcNAc-Phosphotransferase (GPT)

Products are for research use only. Not for human use. We do not sell to patients.

Tunicamycin Mixture Chemische Struktur

Cas No.: 11089-65-9

Größe Preis Lagerbestand Menge
1mg
43,00 $
Auf Lager
5mg
117,00 $
Auf Lager
10mg
209,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 4 publications

Description Protocol Chemical Properties Quality Control Product Documents Related Video Related Products

Tunicamycin Mixture is a mixture of homologous nucleoside antibiotics that inhibits N-glycosylation and blocks GlcNAc phosphotransferase (GPT)[1]. Tunicamycin Mixture can induce cellular endoplasmic reticulum (ER) stress and lead to blockage of DNA synthesis and G1 phase arrest [2]. Tunicamycin Mixture inhibits Gram-positive bacteria, yeast, fungi and viruses and has anti-cancer activity [3].

In vitro, pretreatment of RAW264.7 cells with Tunicamycin Mixture (0.5μg/ml) for 2h significantly reduced LPS-induced nitrite production and weakened the expression of iNOS and COX-2 mRNA and protein[4]. Tunicamycin Mixture (1-20μg/ml) treated prostate cancer PC-3 cells for 24-96h, dose-dependently reduced cell viability, blocked the formation of N-glycosylation in proteins and induced endoplasmic reticulum stress [5] .

In vivo, Tunicamycin Mixture (1mg/kg) treated mice via intraperitoneal injection, significantly increased hepatic triglyceride accumulation, inhibited hepatic lipoprotein secretion, and reduced blood glucose levels and liver glycogen content [6]. The administration of a Tunicamycin mixture (2μg) via intratracheal delivery in a neutrophilic asthma model (OVALPS-OVA mice) increased the protein expression levels of endoplasmic reticulum stress markers and inflammatory cytokines, leading to a more severe asthma phenotype in the mice [7].

References:
[1] Hsu J L, Chiang P C, Guh J H. Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78[J]. Naunyn-Schmiedeberg's archives of pharmacology, 2009, 380: 373-382.
[2] Han C, Jin L, Mei Y, et al. Endoplasmic reticulum stress inhibits cell cycle progression via induction of p27 in melanoma cells[J]. Cellular signalling, 2013, 25(1): 144-149.
[3] Pałasz A, Cież D. In search of uracil derivatives as bioactive agents. Uracils and fused uracils: Synthesis, biological activity and applications[J]. European journal of medicinal chemistry, 2015, 97: 582-611.
[4] Kim S Y, Hwang J S, Han I O. Tunicamycin inhibits Toll-like receptor-activated inflammation in RAW264. 7 cells by suppression of NF-κB and c-Jun activity via a mechanism that is independent of ER-stress and N-glycosylation[J]. European journal of pharmacology, 2013, 721(1-3): 294-300.
[5] Guha P, Kaptan E, Gade P, et al. Tunicamycin induced endoplasmic reticulum stress promotes apoptosis of prostate cancer cells by activating mTORC1[J]. Oncotarget, 2017, 8(40): 68191.
[6] Feng B, Huang X, Jiang D, et al. Endoplasmic reticulum stress inducer tunicamycin alters hepatic energy homeostasis in mice[J]. International journal of molecular sciences, 2017, 18(8): 1710.
[7]Guo Q, Li H, Liu J, et al. Tunicamycin aggravates endoplasmic reticulum stress and airway inflammation via PERK-ATF4-CHOP signaling in a murine model of neutrophilic asthma[J]. Journal of Asthma, 2017, 54(2): 125-133.

Bewertungen

Review for Tunicamycin Mixture

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tunicamycin Mixture

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.